Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Efficacy of Ultra-low Doses of Alkylating Drug Melphalan Inhalations for the Treatment of Non-cystic Fibrosis Bronchiectasis

NCT04278040 is registered in ClinicalTrials.gov with Federal State Budgetary Institution, Pulmonology Scientific Research Institute as lead sponsor.

NCT NCT04278040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04278040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Efficacy of Ultra-low Doses of Alkylating Drug Melphalan Inhalations for the Treatment of Non-cystic Fibrosis Bronchiectasis
Lead sponsor
Federal State Budgetary Institution, Pulmonology Scientific Research Institute
Phase
Phase 2
Overall status
Unknown status
Start date
June 20, 2018
Completion date
December 30, 2021
Enrollment
7 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-cystic fibrosis bronchiectasis